Viewing Study NCT02152956


Ignite Creation Date: 2025-12-24 @ 11:20 PM
Ignite Modification Date: 2026-02-20 @ 8:08 PM
Study NCT ID: NCT02152956
Status: TERMINATED
Last Update Posted: 2024-01-30
First Post: 2014-05-28
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Sponsor: MacroGenics
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None AML View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AML View
None leukemia View
None myelogenous View
None myeloid View
None refractory View